Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1334

1.

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).

van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Pharmacol Res. 2019 Jun 5;146:104297. doi: 10.1016/j.phrs.2019.104297. [Epub ahead of print]

PMID:
31175939
2.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N.

Eur J Clin Pharmacol. 2019 Jun 7. doi: 10.1007/s00228-019-02704-2. [Epub ahead of print]

PMID:
31175385
3.

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Li W, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:78-82. doi: 10.1016/j.jchromb.2019.05.026. Epub 2019 May 27.

PMID:
31163324
4.

Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study.

Arnamo AH, Huitema AD, Beijnen JH, Nuijen B.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850297. doi: 10.1177/1078155219850297. [Epub ahead of print]

PMID:
31156055
5.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.

van Bussel MTJ, Beijnen JH, Brandsma D.

BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.

6.

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 5;173:169-175. doi: 10.1016/j.jpba.2019.05.037. Epub 2019 May 21.

PMID:
31146172
7.

Host-mediated activity of miltefosine in leishmaniasis through immunomodulation: a systematic review.

Palić S, Bhairosing P, Beijnen JH, Dorlo TPC.

Antimicrob Agents Chemother. 2019 Apr 29. pii: AAC.02507-18. doi: 10.1128/AAC.02507-18. [Epub ahead of print]

8.

Predictive Value of Microdose Pharmacokinetics.

van Nuland M, Rosing H, Huitema ADR, Beijnen JH.

Clin Pharmacokinet. 2019 Apr 27. doi: 10.1007/s40262-019-00769-x. [Epub ahead of print] Review.

PMID:
31030372
9.

LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.

van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Jun 5;170:161-168. doi: 10.1016/j.jpba.2019.03.043. Epub 2019 Mar 20.

PMID:
30925273
10.

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. doi: 10.1016/j.jchromb.2019.02.017. Epub 2019 Feb 16.

11.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

12.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.

PMID:
30754019
13.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
14.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

Durmus S, van der Valk M, Teunissen SF, Song JY, Wagenaar E, Beijnen JH, Schinkel AH.

Arch Toxicol. 2019 Mar;93(3):775-790. doi: 10.1007/s00204-019-02394-w. Epub 2019 Jan 30.

PMID:
30701287
15.

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Eur J Pharm Biopharm. 2019 Mar;136:120-130. doi: 10.1016/j.ejpb.2019.01.016. Epub 2019 Jan 17.

PMID:
30660696
16.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 1;1106-1107:26-34. doi: 10.1016/j.jchromb.2019.01.001. Epub 2019 Jan 3.

17.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2019 Apr;17(2):e383-e386. doi: 10.1016/j.clgc.2018.12.004. Epub 2018 Dec 19. No abstract available.

18.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
19.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM.

Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.

PMID:
30608567
20.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.

Int J Pharm. 2019 Feb 10;556:172-180. doi: 10.1016/j.ijpharm.2018.12.014. Epub 2018 Dec 12.

PMID:
30553002
21.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
22.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
23.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
24.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:167-172. doi: 10.1016/j.jchromb.2018.10.023. Epub 2018 Oct 30.

25.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM.

J Pharm Biomed Anal. 2019 Feb 5;164:128-134. doi: 10.1016/j.jpba.2018.10.025. Epub 2018 Oct 17.

PMID:
30368118
26.
27.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
28.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM.

Nucleosides Nucleotides Nucleic Acids. 2018;37(8):436-454. doi: 10.1080/15257770.2018.1498270. Epub 2018 Oct 4.

PMID:
30285552
29.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2.

PMID:
30279580
30.

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Nov;137:47-55. doi: 10.1016/j.phrs.2018.09.020. Epub 2018 Sep 22.

PMID:
30253203
31.

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O.

Mol Pharm. 2018 Nov 5;15(11):5236-5243. doi: 10.1021/acs.molpharmaceut.8b00742. Epub 2018 Oct 5.

PMID:
30252484
32.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Mol Pharm. 2018 Nov 5;15(11):5124-5134. doi: 10.1021/acs.molpharmaceut.8b00702. Epub 2018 Oct 10.

PMID:
30247919
33.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

de Vries Schultink AHM, Huitema ADR, Beijnen JH.

Breast. 2018 Dec;42:38-40. doi: 10.1016/j.breast.2018.08.100. Epub 2018 Aug 22.

PMID:
30153552
34.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Nov 30;161:136-143. doi: 10.1016/j.jpba.2018.08.038. Epub 2018 Aug 19.

PMID:
30149189
35.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
36.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

37.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

38.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O.

Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w.

39.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Nov;172(1):143-150. doi: 10.1007/s10549-018-4886-8. Epub 2018 Jul 13.

40.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4.

PMID:
29974200
41.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC.

Front Cell Infect Microbiol. 2018 Jun 1;8:181. doi: 10.3389/fcimb.2018.00181. eCollection 2018.

42.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.

PMID:
29883879
43.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2019 Mar;58(3):299-308. doi: 10.1007/s40262-018-0683-0. Review.

PMID:
29862467
44.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

45.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:14-21. doi: 10.1016/j.jchromb.2018.05.011. Epub 2018 May 11.

46.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.

PMID:
29757380
47.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.

48.

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.

Int J Cancer. 2018 Oct 15;143(8):2029-2038. doi: 10.1002/ijc.31582. Epub 2018 Jul 10.

PMID:
29744867
49.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR.

Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5.

50.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279

Supplemental Content

Loading ...
Support Center